{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:47:57Z","timestamp":1784335677220,"version":"3.55.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The endothelial glycocalyx (EG) is essential for proper function of the endothelium and for vascular integrity, but its role in premature atherogenesis in rheumatoid arthritis (RA) has not been studied yet. EG impairment can play a role in pathogenesis of vascular disease, and one of its characteristics is shedding of syndecan-1 from endothelial cells. Syndecan-1 shedding is mediated by matrix metalloproteinase-9 (MMP-9) and counteracted by tissue inhibitor of metalloproteinases (TIMP)-1. Cardiovascular disease risk in RA is reversible by disease modifying antirheumatic drugs (DMARDs), but the exact modes of action are still unclear. Therefore, we examined effects of DMARDs on syndecan-1, MMP-9 and TIMP-1 in RA patients, and searched for associations between these parameters and inflammatory activity. From the observational PSARA study, we examined 39 patients starting with methotrexate (MTX) monotherapy (in MTX na\u00efve patients, n = 19) or tumor necrosis factor inhibitors (TNFi) in combination with MTX (in MTX non-responders, n = 20) due to active RA. Serum syndecan-1, MMP-9 and TIMP-1 were measured at baseline and after six weeks of treatment. Serum syndecan-1 (<jats:italic>p<\/jats:italic> = 0.008) and TIMP-1 (<jats:italic>p<\/jats:italic>&lt;0.001) levels decreased after six weeks of anti-rheumatic treatment. Levels of MMP-9 also decreased, but the difference was not statistically significant. The improvement in syndecan-1 levels were independent of changes in inflammatory activity. There was no significant difference in changes in syndecan-1 levels from baseline to 6 weeks between the MTX and TNFi groups, however the change was significant within the MTX group. Six weeks of antirheumatic treatment was associated with reduction in serum levels of syndecan-1, which might reflect reduced syndecan-1 shedding from EG. Thus, it is possible that EG-preserving properties of DMARDs might contribute to their cardioprotective effects. These effects may be at least partly independent of their anti-inflammatory actions. Our findings do not support the notion that syndecan-1 shedding in RA is mediated mainly by increased MMP-9 or decreased TIMP-9 serum concentration.<\/jats:p>","DOI":"10.1371\/journal.pone.0253247","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T17:56:05Z","timestamp":1625853365000},"page":"e0253247","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6143-1600","authenticated-orcid":true,"given":"Gia","family":"Deyab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Marita","family":"Reine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tram Thu","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Jenssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnbj\u00f8rg","family":"Hjeltnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"F\u00f8rre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Wang","family":"Fagerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein Olav","family":"Kolset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Hollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"9","key":"pone.0253247.ref001","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"D Aletaha","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"pone.0253247.ref002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(97)00189-7","article-title":"Endothelial Dysfunction: Does It Matter? Is It Reversible?","volume":"30","author":"DS Celermajer","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"pone.0253247.ref003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.rdc.2010.02.002","article-title":"Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment","volume":"36","author":"MJ Kaplan","year":"2010","journal-title":"Rheumatic diseases clinics of North America"},{"issue":"5","key":"pone.0253247.ref004","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.39039","article-title":"Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism","volume":"67","author":"N Ronda","year":"2015","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"3","key":"pone.0253247.ref005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bcp.12629","article-title":"Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases","volume":"80","author":"BF Becker","year":"2015","journal-title":"British journal of clinical pharmacology"},{"issue":"7","key":"pone.0253247.ref006","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1083\/jcb.201501060","article-title":"Transmembrane proteoglycans control stretch-activated channels to set cytosolic calcium levels","volume":"210","author":"S Gopal","year":"2015","journal-title":"The Journal of cell biology"},{"key":"pone.0253247.ref007","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-cellbio-100109-104126","article-title":"Transmembrane signaling proteoglycans","volume":"26","author":"JR Couchman","year":"2010","journal-title":"Annu Rev Cell Dev Biol"},{"key":"pone.0253247.ref008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-014-0279-8","article-title":"Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells","volume":"14","author":"HC Lim","year":"2015","journal-title":"Molecular cancer"},{"issue":"5","key":"pone.0253247.ref009","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0955-0674(00)00254-4","article-title":"Syndecan-4 and focal adhesion function","volume":"13","author":"A Woods","year":"2001","journal-title":"Current opinion in cell biology"},{"issue":"19","key":"pone.0253247.ref010","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1111\/j.1742-4658.2010.07798.x","article-title":"Proteoglycans in health and disease: the multiple roles of syndecan shedding","volume":"277","author":"T Manon-Jensen","year":"2010","journal-title":"Febs J"},{"issue":"8","key":"pone.0253247.ref011","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nri1418","article-title":"Matrix metalloproteinases as modulators of inflammation and innate immunity","volume":"4","author":"WC Parks","year":"2004","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"pone.0253247.ref012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbamcr.2010.01.003","article-title":"The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity","volume":"1803","author":"K Brew","year":"2010","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Molecular Cell Research"},{"key":"pone.0253247.ref013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fimmu.2020.00227","article-title":"Syndecans in Inflammation at a Glance","volume":"11","author":"S Gopal","year":"2020","journal-title":"Front Immunol"},{"key":"pone.0253247.ref014","article-title":"Syndecans in chronic inflammatory and autoimmune diseases: pathological insights and therapeutic opportunities","author":"SA Agere","year":"2017","journal-title":"J Cell Physiol"},{"issue":"Suppl","key":"pone.0253247.ref015","article-title":"Syndecan-4 is a key regulator of Osteoarthritic cartilage damage","volume":"60","author":"J Bertrand","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"pone.0253247.ref016","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/ar4610","article-title":"Syndecan-3 is selectively pro-inflammatory in the joint and contributes to antigen-induced arthritis in mice","volume":"16","author":"O Kehoe","year":"2014","journal-title":"Arthritis research & therapy"},{"key":"pone.0253247.ref017","article-title":"MMP-9 mediated Syndecan-4 shedding correlates with osteoarthritis severity","author":"M Bollmann","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"issue":"2","key":"pone.0253247.ref018","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clin.1996.0025","article-title":"Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker","volume":"78","author":"BL Gruber","year":"1996","journal-title":"Clinical immunology and immunopathology"},{"key":"pone.0253247.ref019","doi-asserted-by":"crossref","first-page":"545493","DOI":"10.1155\/2014\/545493","article-title":"Cytokines as biomarkers in rheumatoid arthritis","volume":"2014","author":"A Burska","year":"2014","journal-title":"Mediators of inflammation"},{"key":"pone.0253247.ref020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13075-015-0652-z","article-title":"Early biomarkers of joint damage in rheumatoid and psoriatic arthritis","volume":"17","author":"A Mc Ardle","year":"2015","journal-title":"Arthritis research & therapy"},{"issue":"Suppl 2","key":"pone.0253247.ref021","first-page":"ii43","article-title":"Metalloproteinases, inflammation, and rheumatoid arthritis","volume":"62","author":"FF Mohammed","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"pone.0253247.ref022","doi-asserted-by":"crossref","first-page":"e0169830","DOI":"10.1371\/journal.pone.0169830","article-title":"Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"12","author":"G Deyab","year":"2017","journal-title":"PloS one"},{"issue":"3","key":"pone.0253247.ref023","first-page":"415","article-title":"Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-alpha-inhibitor","volume":"31","author":"G Hjeltnes","year":"2013","journal-title":"Clinical and experimental rheumatology"},{"issue":"7","key":"pone.0253247.ref024","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3899\/jrheum.111401","article-title":"Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-alpha inhibitors","volume":"39","author":"G Hjeltnes","year":"2012","journal-title":"The Journal of rheumatology"},{"issue":"3","key":"pone.0253247.ref025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"6","key":"pone.0253247.ref026","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/03009742.2011.585350","article-title":"Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients","volume":"40","author":"G Hjeltnes","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"pone.0253247.ref027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1358863X12436708","article-title":"Reproducibility of different methods to measure the endothelial function","volume":"17","author":"S Onkelinx","year":"2012","journal-title":"Vascular medicine (London, England)"},{"issue":"10","key":"pone.0253247.ref028","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0735-1097(03)00329-2","article-title":"Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease","volume":"41","author":"PO Bonetti","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"pone.0253247.ref029","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/03009742.2012.656698","article-title":"Endothelial function improves within 6 weeks of treatment with methotrexate or methotrexate in combination with a TNF-alpha inhibitor in rheumatoid arthritis patients","volume":"41","author":"G Hjeltnes","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"pone.0253247.ref030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00277-002-0437-8","article-title":"Syndecan-1 in B lymphoid malignancies","volume":"81","author":"RD Sanderson","year":"2002","journal-title":"Ann Hematol"},{"issue":"3","key":"pone.0253247.ref031","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0267659108098215","article-title":"Syndecan-1 plasma levels during coronary artery bypass surgery with and without cardiopulmonary bypass","volume":"23","author":"K Svennevig","year":"2008","journal-title":"Perfusion"},{"key":"pone.0253247.ref032","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.08.005","article-title":"Gender differences in the association of syndecan-4 with myocardial infarction: The population-based Troms\u00f8 Study","volume":"278","author":"MD Solbu","year":"2018","journal-title":"Atherosclerosis"},{"issue":"19","key":"pone.0253247.ref033","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1111\/j.1742-4658.2010.07798.x","article-title":"Proteoglycans in health and disease: the multiple roles of syndecan shedding","volume":"277","author":"T Manon-Jensen","year":"2010","journal-title":"Febs j"},{"issue":"4","key":"pone.0253247.ref034","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1369\/0022155415568995","article-title":"Syndecan-4 is a major syndecan in primary human endothelial cells in vitro, modulated by inflammatory stimuli and involved in wound healing","volume":"63","author":"TT Vuong","year":"2015","journal-title":"J Histochem Cytochem"},{"key":"pone.0253247.ref035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13049-016-0239-y","article-title":"The endothelial glycocalyx and its disruption, protection and regeneration: a narrative review","volume":"24","author":"U Sch\u00f6tt","year":"2016","journal-title":"Scand J Trauma Resusc Emerg Med"},{"issue":"2","key":"pone.0253247.ref036","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3899\/jrheum.140568","article-title":"Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus","volume":"42","author":"KJ Kim","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"pone.0253247.ref037","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1183\/09031936.00146510","article-title":"Series \"matrix metalloproteinases in lung health and disease\": Biological role of matrix metalloproteinases: a critical balance","volume":"38","author":"S Loffek","year":"2011","journal-title":"The European respiratory journal"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T17:56:54Z","timestamp":1625853414000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253247"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0253247","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}